ClearPoint Neuro (CLPT) Projected to Post Earnings on Wednesday

ClearPoint Neuro (NASDAQ:CLPT) is expected to release its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect ClearPoint Neuro to post earnings of ($0.22) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, March 4, 2026 at 4:30 PM ET.

ClearPoint Neuro Stock Up 4.3%

NASDAQ:CLPT opened at $14.76 on Tuesday. The business’s fifty day moving average price is $14.10 and its 200 day moving average price is $15.60. The firm has a market capitalization of $419.48 million, a price-to-earnings ratio of -17.57 and a beta of 1.01. The company has a current ratio of 6.37, a quick ratio of 5.56 and a debt-to-equity ratio of 1.84. ClearPoint Neuro has a 1-year low of $9.76 and a 1-year high of $30.10.

Analysts Set New Price Targets

CLPT has been the topic of several analyst reports. Wall Street Zen downgraded ClearPoint Neuro from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ClearPoint Neuro in a report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $9.00.

Insider Buying and Selling

In other news, CEO Joseph Burnett sold 2,943 shares of the stock in a transaction on Monday, January 26th. The stock was sold at an average price of $15.57, for a total transaction of $45,822.51. Following the sale, the chief executive officer owned 214,116 shares in the company, valued at approximately $3,333,786.12. This represents a 1.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 6.11% of the stock is currently owned by company insiders.

Institutional Trading of ClearPoint Neuro

Several institutional investors and hedge funds have recently made changes to their positions in CLPT. Caitong International Asset Management Co. Ltd acquired a new stake in ClearPoint Neuro in the fourth quarter worth $25,000. BNP Paribas Financial Markets raised its stake in ClearPoint Neuro by 2,435.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,231 shares of the company’s stock worth $27,000 after buying an additional 2,143 shares during the period. Legal & General Group Plc acquired a new stake in ClearPoint Neuro during the 2nd quarter worth $35,000. Russell Investments Group Ltd. lifted its holdings in ClearPoint Neuro by 1,079.0% during the third quarter. Russell Investments Group Ltd. now owns 2,358 shares of the company’s stock worth $51,000 after acquiring an additional 2,158 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in ClearPoint Neuro in the second quarter valued at about $80,000. Institutional investors own 30.08% of the company’s stock.

About ClearPoint Neuro

ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company’s flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.

The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.